Chapter from the book *Glaucoma - Current Clinical and Research Aspects*
Downloaded from: http://www.intechopen.com/books/glaucoma-current-clinical-and-research-aspects
Pressure Lowering Medications

Liza-Sharmini Ahmad Tajudin and Yaakub Azhany
Department of Ophthalmology,
School of Medical Sciences,
Universiti Sains Malaysia
Malaysia

1. Introduction

Glaucoma is an irreversible chronic disease; thus, management is a great challenge. The main goal of treatment is to prevent further nerve fibre damage. The present modes of treatment include pressure-lowering medications, laser treatment, and surgical interventions, all of which aim to reduce IOP. Diversion of aqueous humour outflow through an iatrogenic fistula to the sub-conjunctival space is the principle underlying glaucoma surgery. Surgical intervention provides sustainable constant IOP reduction but not without intra- and postoperative complications (Migdal et al, 1994; Musch et al, 2009). In fact, glaucoma surgery hastens cataract formation, which may necessitate further surgical intervention (Musch et al, 2009; AGIS group, 2000). Surgical equipment, a proper operating theatre, and an experienced surgeon increase the cost of filtration surgery. The invasiveness of the procedure interrupts the natural defence mechanism of the eye, increasing the risk of infection. Laser treatment is less invasive and is associated with a lower risk of infection. Similar to the filtration surgery, it is a permanent procedure and does not require a high technology environment but requires an expensive high-maintenance laser machine. However, the pressure-lowering effect is insufficient and temporary (Glaucoma Laser Trial Research Group, 1995). Manipulation of aqueous humour production and outflow is the mainstay mechanism of topical pressure-lowering medications. Topical medications are widely available in industrialised nations, are non-invasive and easily transportable. In addition, they are relatively easy to instil without the need for special equipment or a high technology environment. Importantly, unlike surgical or laser treatment, it is non-permanent and easily discontinued if it is ineffective or produces unwanted side effects.

Topical pressure lowering medications was previously known as topical antiglaucoma drugs. However, many glaucomatologist deem the term inappropriate. The medications do not at all reverse the condition or totally halt the progression of glaucoma. In this chapter, the term pressure lowering medications or drugs will be used. The sprouting of new more effective pressure lowering medications has widened the choice of medications and at time cause difficulty in the selection of medication. Table 1.0 provide an overview on commonly available pressure lowering medication in the market currently. A guideline on selection of topical pressure lowering medications will be discussed in this chapter.
<table>
<thead>
<tr>
<th>Group</th>
<th>Mode of action</th>
<th>Drugs (concentration)</th>
<th>Dose</th>
<th>IOP reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parasympathomimetics</strong></td>
<td>Increased aqueous outflow</td>
<td>Pilocarpine (0.25-4%)</td>
<td>TID or QID</td>
<td>20-25%</td>
</tr>
<tr>
<td><strong>Sympathomimetics</strong></td>
<td>Non-selective (Decrease aqueous production and increase outflow)</td>
<td>Epinephrine (0.25-2.0%)</td>
<td>TID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selective</td>
<td>Dipiverfin (0.1%)</td>
<td>BD</td>
<td></td>
</tr>
<tr>
<td><strong>Carbonic anhydrase inhibitor</strong></td>
<td>Decrease aqueous production</td>
<td>Dorzolamide (2%)</td>
<td>BD or TID</td>
<td>15-20%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brinzolamide (1%)</td>
<td>TID</td>
<td></td>
</tr>
<tr>
<td><strong>Beta adrenoreceptor antagonist</strong></td>
<td>Non-selective (Decrease aqueous production)</td>
<td>Timolol (0.1, 0.25, 0.5%)</td>
<td>BD</td>
<td>20-25%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Levobunolol (0.25, 0.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timolol GFS (0.25, 0.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selective</td>
<td>Betaxolol (0.25, 0.5%)</td>
<td>BD</td>
<td>15-20%</td>
</tr>
<tr>
<td><strong>Prostaglandin analog</strong></td>
<td></td>
<td>Latanoprost (0.005%)</td>
<td>Once a day</td>
<td>25-30%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Travaprost (0.004%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unoprostone (0.12, 0.15%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bimatoprost (0.03%)</td>
<td>Once a day</td>
<td>25-30%</td>
</tr>
</tbody>
</table>

Table 1.0. Commercially available topical pressure lowering drugs

2. Beta antagonists

The potential benefit of systemic β-adrenoreceptor antagonists in lowering IOP was initially evaluated and intravenous propanolol was found to be the most effective (Philips et al,
The profound corneal anaesthesia induced by propanolol, however, outweighs its potential utility. Intensive ophthalmic research eventually led to the introduction of topical timolol. In 1978, topical timolol revolutionized glaucoma management and is now the first-line treatment for glaucoma.

Topical β-blocker acts predominantly by decreasing aqueous humour production without any effect on outflow capacity, despite the presence of ADRB2 in the trabecular meshwork (Coakes and Brubaker, 1978; Yablonski and Zimmerman, 1978; Sonntag et al, 1978). β-Blocker action is predominantly mediated by the ADRB2 receptor, abundantly found in the ciliary epithelium and ciliary body. Aqueous humour is produced by ciliary bodies through ultra-filtration and active secretion by the ciliary epithelium. The reversible β-blocker binding prevents binding of catecholamine that in turn prevents activation of intracellular adenylate cyclase and reduces the intracellular concentration of cAMP at the ciliary body. Through an unknown mechanism, this process reduces aqueous humour production (Neufeld, 1979). The basal level of cAMP is maintained, as is the response to other transmitters. cAMP is an important second messenger in the intracellular cascade. Since the understanding of aqueous humour production is imprecise, the mechanism of action of topical β-blocker remains unknown.

β-blocker has a less potent effect on β1-adrenoreceptor in decreasing cAMP synthesis (Juzych and Zimmerman, 1997). Serotonin receptor, particularly 5-HT1A, is abundant in the iris and ciliary body and has a similar molecular structure as ADRB2 receptor, but has a negative impact on the adenyllyl-cyclase cAMP cascade (Osborne and Chidlow, 1996). Timolol demonstrated high affinity towards 5-HT1A in the ciliary process of rabbits, which further supports the effect of timolol as a suppressor of aqueous humour production (Osborne and Chidlow, 1996).

Although the classic association of reduced cAMP synthesis and aqueous humour production is widely accepted, other evidence disputes this postulation. Schmitt et al (1980) found no association between decreased cAMP and the pressure-lowering effect of β-blockers on rabbits. Drugs that increase intracellular cAMP such as forskolin and cholera toxin also reduce the IOP, which contradicts the previous popular hypothesis (Caprioli et al, 1984). Another hypothesis postulated that the reduction of aqueous humour formation is achieved by direct inhibition of adrenergic stimulation of the secretory ciliary epithelium by endogenous epinephrine (Topper and Brubaker, 1985). Decreased ocular blood flow induced by β-blockers provides another alternative hypothesis. The effect of β-blockers on the vascular smooth muscle of the ciliary body inhibits vasodilatation and induces vasoconstriction of ciliary arterioles, which reduces capillary perfusion and stromal ultrafiltration (Vareilles et al, 1977). Reduction of aqueous humour production is an indirect consequence of decreases ocular blood flow (Watanabe and Chiou, 1983). There is also direct evidence that dopamine plays a role in ocular blood circulation. Haloperidol, a dopamine-blocking agent, reduces IOP.

For more than 3 decades, the topical β-blockers, particularly timolol, have been proven effective ocular hypotensive drugs in many types of glaucoma. Currently, there are five topical beta blockers available worldwide; timolol maleate, betaxolol hydrochloride, levobunolol hydrochloride, carteolol hydrochloride and metipranolol (Table 1.1). Although the aqueous solution of timolol maleate is widely used but recently the gel forming solution has been introduced and well accepted. Gel forming solution is prepared from purified P.elodea cell wall that forms gel solution once in contact with monovalent and divalent cations in tear film. This novel ophthalmic vehicle provides similar pressure lowering effect.
as the aqueous form with just once a day dosing (Shedden et al, 2001). It is believed to reduce the possible systemic adverse effects but with higher reported incidence of transient blurring of vision (Dickstein et al, 2001; Stewart et al, 1999). Topical beta blockers are inexpensive especially in the generic form that further increased their popularity especially in developing countries. It is still the treatment of choice in many parts of the world.

<table>
<thead>
<tr>
<th>Property</th>
<th>Timolol</th>
<th>Betaxolol</th>
<th>Levobunolol</th>
<th>Carteolol</th>
<th>Metipranolol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentrations (%)</td>
<td>0.25, 0.5</td>
<td>0.25, 0.5</td>
<td>1.0</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>Preservatives</td>
<td>BAC#</td>
<td>BAC#</td>
<td>BAC#</td>
<td>BAC#</td>
<td>BAC#</td>
</tr>
<tr>
<td></td>
<td>0.01%</td>
<td>0.004%</td>
<td>0.005%</td>
<td>0.004%</td>
<td></td>
</tr>
<tr>
<td>Beta blocker potency*</td>
<td>4.7</td>
<td>1.0</td>
<td>14.6</td>
<td>10.0</td>
<td>1.8</td>
</tr>
<tr>
<td>Serum half life (hrs)</td>
<td>12-20</td>
<td>6</td>
<td>3-7</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Cardioselective</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Intrinsic syntaphomimetic</td>
<td>-</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Ocular discomfort</td>
<td>++</td>
<td>++</td>
<td>±</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Systemic side effect</td>
<td>±</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Decrease heart rate</td>
<td>++</td>
<td>±</td>
<td>++</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Respiratory impairment</td>
<td>++</td>
<td>?</td>
<td>?</td>
<td>-</td>
<td>?</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>±</td>
<td>?</td>
<td>±</td>
<td>?</td>
<td></td>
</tr>
</tbody>
</table>

* beta blockade potency as compared to propanolol (propanolol=1)  
#BAC: benzylkonium chloride  
? No data available or inconclusive data

Table 1.1. Properties of beta blockers

2.1 Topical timolol

Topical timolol is a lipophilic, non-cardio-selective β antagonist without intrinsic sympathomimetic activity. It also lacks the ability to act as partial agonist and lacks membrane-stabilizing ability. Its chemical name is (-)-1-(tert-butylamino)-3-[4-morpholino-1,2,5-thiazole-3-yl] oxy]-2 propanol maleate (1:1) (salt). The asymmetrical carbon atom in its structure forms a laevo-isomer (Figure 1.3). The optical rotation of timolol maleate is \[\alpha_{[\text{in}1.0\text{NHCl(C - 5%)]}^{25^\circ}} = -12.2^\circ (\text{-11.7^\circ to -12.5^\circ})\] with a molecular weight of 432.50.

It is an enantiomer; D- and L-enantiomers are stereo-isomers that are non-super-imposable mirror images of each other.
Timolol maleate is a white crystalline powder soluble in water, methanol, and alcohol, with a pKa of approximately 9 in water at 25°C. It is available as a sterile, isotonic, buffered aqueous solution with pH approximately 7.0 and osmolarity of 274–328 mOsm. There are also inactive ingredients such as monobasic and dibasic sodium phosphate, sodium hydroxide for pH adjustment, and water for injection. Benzalkonium chloride 0.01% is added as a preservative. Timolol maleate as the pure chemical is extremely stable to light and temperature, but the formulated topical form is less stable with a shelf life of 2 years.

Fig. 1.0. Chemical structure and formula of timolol maleate

The ocular hypotensive effect of timolol is more profound when administered orally but significant effect is also achieved topically. Although the ocular hypotensive effect of topical timolol is achieved at a concentration as low as 0.008%, the optimal therapeutic dose is 0.25% and 0.5% twice daily in aqueous solution. The active ingredient in each millilitre of 0.25% of timolol maleate contains 2.5 mg of timolol (3.4 mg of timolol maleate) and each millilitre of 0.5% contains 5 mg of timolol (6.8 mg of timolol maleate). The concentration of timolol in the anterior chamber reaches 1–2 µM (8–100 ng/mL) after an hour of topical instillation, which is much higher than the minimum amount required to bind ADRB2 in the ciliary body (Philips et al, 1985). Thus, the pressure-lowering effect is achieved just 20 to 30 minutes after instillation with the peak seen 2 hours post instillation (Zimmerman and Kaufman, 1977). This is followed by further pressure reduction that is sustained up to 24 hours. Surprisingly, the half-life of topical timolol is just 1.5 hours (Schmitt et al, 1980).

Reversible binding of timolol to ocular melanin provides a reservoir for slow release of the active drug and is responsible for prolonging the pressure-lowering effect of timolol despite its short half-life. Animal studies have shown that timolol has a high affinity for and binds easily to melanin. Dark-pigmented rabbits demonstrated higher concentration of timolol maleate in the iris ciliary body when compared to albino rabbits, reducing the amount of active ingredient available for pharmacological action (Menon et al, 1989). Melanin near to the site of pharmacological action did not inactivate the active drug. Paradoxically, melanin competitively inhibits timolol. The net effect is that highly pigmented eyes require a higher concentration than less pigmented eyes, which is reflected in clinical observations in Asians and Africans (Ong et al, 2005; Otaleju and Ajayi, 1999; Katz and Berger, 1979).

Zimmerman and Kaufman (1977) reported the first 24-hour dose response to topical timolol 0.25% and 0.5% was similar. Maximum pressure reduction was reported to be nearly 40% in glaucoma patients treated with 0.5% topical timolol in short- and long-term dose-response
studies (Zimmerman and Kaufmann, 1977; Boger et al, 1978; Lin et al, 1979). The pressure-lowering effect is best in daytime and poor at night, when aqueous humour production is reduced to less than half. In its early days, the effectiveness of timolol was compared only to topical pilocarpine and epinephrine, and was found to be significantly more effective with the added advantage of less frequent dosing (Boger et al, 1978; Zimmerman and Boger, 1979). The effectiveness of timolol has earned it status as the ‘gold standard’ used as the comparator for other new drugs that have flourished the glaucoma pharmaceutical market.

Topical timolol is effective in nearly all types of glaucoma including refractory glaucomas such as neovascular, aphakic, and uveitic glaucoma (Weber, 1981, Lin et al, 1979). Perhaps, due to its suppressive effect on aqueous humour production, it is also effective in angle-closure glaucoma (Lass and Pavan-Langston, 1979; Chew et al, 2004). Long-term treatment with timolol has been proven effective, but the effect is not sustained in more than half of patients after 5 years (Watson et al, 2001). Boger (1979) reported short-term escape and long-term drift phenomena in certain individuals. Upregulation of ADRB2 receptors in the iris and ciliary body is believed to be responsible for blunting the effect of timolol after short-term treatment (Boger, 1979). A meta-analysis comparing a wide range of topical anti-glaucoma drugs and prostaglandin analogue found that timolol is as effective as prostaglandin analogue in providing good IOP reduction at peak and trough (van de Valk et al, 2005). Prostaglandin analogue is slightly but not significantly better than timolol in pressure-lowering effectiveness.

Similar reduction of pressure by timolol was also reported in the contralateral, untreated eye (Dunham et al, 1994; Piltz et al, 2000). Absorption of timolol by the nasopharyngeal mucosa has raised concerns of potentially life-threatening side effects following topical administration (Passo et al, 1984; Diggory and Franks, 1997). The elderly and those with cardio-respiratory impairment are at risk, and prescribing timolol in these patients must be done with caution (Diggory et al, 1998; Diggory et al, 1994; Leier et al, 1986). In spite of great concern regarding the systemic side effect of timolol but there is no evidence suggesting increase in mortality in patients on topical timolol therapy (Musken et al, 2008). Although timolol has some effects on hypoglycaemia and hyperlipidaemia, the effect is minimal with low clinical importance (Coleman et al, 1990; Shorr et al, 1997). Decreased libido, depression, and hallucination are among the reported side effects of timolol (Lama, 2002). Due to the potential cardiorespiratory side effect, timolol is contraindicated in asthmatic or those with history of asthma, severe chronic obstructive pulmonary diseases, severe heart block, overt cardiac failure, bradycardic patients and those with history of allergic to timolol or its preservatives.

The introduction of gel-forming timolol solution has lessened its systemic effect (Shedden et al, 2001). Timolol gel-forming solution (GFS) increases the viscosity of the drug, promotes ocular bioavailability, and facilitates ocular drug penetration. The prolongation of ocular contact depends on the gel formulation, which acts as a physical barrier to drainage or as a viscosity promoter. The gel in Timolol XE 0.5% promotes viscosity and bleb formation, which creates a temporary plug in the inner canthus and impedes timolol drainage through the punctum. Once-daily dosing of timolol GFS provides a similar pressure-lowering effect as timolol maleate in aqueous form with twice-daily instillation in glaucoma and ocular hypertensive patients (Roselund, 1996; Shedden et al, 2001). Plasma concentrations of timolol GFS are significantly lower than timolol ophthalmic solution, which perhaps explains the reduced systemic side effects associated with the gel solution (Shedden et al, 2001; Dickstein et al, 2001; Uusitalo et al, 2006). Blurred vision upon instillation of timolol in gel solution and ocular discomfort were reported in many patients (Shedden et al, 2001).
Ocular allergic reaction is one of the commonest ocular side effects following topical timolol instillation, which can manifest as blepharoconjunctivitis, erythema and edema of the eyelids (Akingbehin and Sunder Raj, 1990). Allergic reaction can occur at any duration of treatment and as early as the first month. Timolol has similar ability as topical propranolol to induce corneal anaesthesia but at lesser extent (van Buskirk, 1980). Superficial punctuate keratitis has been reported and may lead to epitheliopathy and corneal epithelial erosions. Dry eye and reduce break up time has also been documented in patients treated with topical timolol (Kuppens EV et al, 1992; Kuppens EV et al 1995; Fasina O et al, 2008).

2.2 Betaxolol
Betaxolol is a cardioselective beta antagonist with relative specificity for β1-adrenoceptor and without intrinsic sympathetic activity. Based on available evidences, β1-adrenoceptors are thought to be involved in regulating heart rate, rhythm and force (Murphree and Saffitz, 1988). However, the distribution of subtype of β-adrenoceptors is more complex than it is believed to be (Carstairs et al, 1985; Satoh et al, 1990). It is believed that the selectivity of certain drug during pre-clinical experiments may not truly reflective in the actual clinical setting.

Betaxolol is a safer alternative for glaucoma patients with mild respiratory impairment due to asthma or other chronic obstructive pulmonary diseases. However, there are reported cases of pulmonary side effect in patients on betaxolol especially in high risk population (Diggory et al, 1994). Even in healthy volunteers, systemic side effects are still present but with lesser degree as compared to metapronalol and timolol (Bauer et al, 1991). There was still unchanged in respiratory symptoms after changing from timolol to betaxolol (Diggory et al, 1994). Perhaps, this is due to the presence of β1 adrenoreceptor in human lung tissue with the ratio of 1:3 (β1: β2) (Carstairs et al, 1985). Betaxolol does not confer total protective effect in patients with respiratory impairment and need to prescribe with caution. Perhaps, prostaglandin analogues provide better protective effect for those with respiratory impairment.

Similar to timolol, betaxolol acts as aqueous suppression through unknown mechanism. However, betaxolol is less potent than timolol as pressure lowering medication. Timolol and levobunolol provides approximately 2 mmHg more IOP reduction compared to betaxolol (Allen et al, 1986; Gaul et al, 1989). Smaller amount of β1 adrenoreceptors in the ocular tissue especially ciliary body as compared to β2 adrenoceptors is postulated to be the causative factor for lack of effectiveness of betaxolol. Topical instillation of betaxolol 0.5% results in plasma level of approximately 0.5ng/ml or half that of timolol 0.25% (Vuori et al, 1993). Betaxolol is the drug of choice in Early Manifest Glaucoma Trial (EMGT). EMGT reported IOP reduction of 25% from baseline with combination of laser trabeculoplasty and topical betaxolol treatment (Heijl et al, 2002). Treatment has significantly reduced the progression of visual field in patients with early stage of glaucoma.

However, the striking benefit of betaxolol than other topical beta blocker is its potential neuroprotective effect. Neuroprotective effect of betaxolol is believed to be due to its ability to block calcium channels on the vessels and retinal ganglion cells (Yu et al, 1999, Wood et al, 2003). It is postulated that the effect of betaxolol on calcium channels is independent of the β-adrenoceptor (Setoguchi et al, 1995). In addition, betaxolol also inhibits glutamate (Hong et al, 2003; Chen et al, 2007). The effect of betaxolol in optic nerve head vasculature is also believed to improve the perfusion and reperfusion of the optic nerve head (Hester et al, 1994, Cheon et al, 2003). However, the clinical effectiveness of betaxolol as neuroprotective
is rather inconclusive. Although there are evidence suggesting the effectiveness of betaxolol in halting the progression of glaucoma but the association is not strong enough (Messmer et al, 1991; Araie et al, 2003).

2.3 Other beta antagonists
Levobunolol, metipranolol and carteolol are non-selective topical β blockers without significant intrinsic sympathomimetic activity, which require metabolism to their active metabolites to achieve their function. Levobunolol is metabolized to dihydrobunolol that has similar potency as timolol at β_2_ adrenoreceptor found in the iris and ciliary body (Wax and Molinoff, 1987). It is available in 0.25% and 0.5%, effective both as once daily dosing as well as twice daily (Wandell et al, 1988). Metipranolol is metabolized to des-acetyl-metipranolol. It is an effective as pressure lowering effect with concentration ranging from 0.1% to 0.6% (Mirza et al, 2000). There is also evidence of increase in retinal perfusion pressure and blood flow in patients treated with metipranolol (Wolfs et al, 1998). Peculiarly, drug induced anterior uveitis has been associated with metipranolol treatment (Watanabe and Hodes, 1997). Similar to levobunalol and metipranolol, carteolol is metabolized to active metabolite, 8-hydroxycarteolol. Unlike other topical β blockers, carteolol possesses intrinsic sympathomimetic activity. Although carteolol is less irritating than 0.5% timolol but moderate corneal anaesthesia has been reported (Bartlett et al, 1999). Carteolol appears to have negligible effect on serum lipid profile (Stewart et al, 1999).

3. Prostaglandin analogues
For 25 years, topical timolol maleate has been widely accepted as the treatment of choice for glaucoma. It is undoubtedly efficacious in almost all types of glaucoma. A lack of intolerable side effects in comparison to topical non-selective sympathomimetics and mitotics further contributed to the popularity of topical timolol. The quest for more potent agents began in the early 1980s. During the frenzy of interest in prostaglandin’s possible ocular anti-inflammatory effects and potential therapeutic role, prostaglandin was infused into cannulated experimental animal eyes and was found to cause ocular hypertension with breakdown of the blood-aqueous barrier (Bito et al, 1989a). Accidentally, the ocular hypotensive effect was achieved with a low concentration of topical prostaglandin with breakdown of the blood-aqueous barrier even without cannulation. Naturally occurring prostaglandins are relatively polar, hydrophilic molecules that poorly cross biological membranes due to their carboxylic acid moiety and several hydroxyl groups. Prostaglandin effects differ between species (Bito et al, 1989b). Different prostanoids have different side effects on the human eye, consistent with the reported multiplicity and low selectivity of naturally occurring prostaglandin for different subtypes of prostanoids (Woodward et al, 1997).

The was a major setback in the first experiment with topical prostaglandin in human volunteers using a high concentration (200 µg) tromethamine salt form of PGF₂α, which resulted in severe ocular hyperaemia, ocular pain, and headache (Giuffre, 1985). Lower concentrations (up to 100-fold) were found to potentiate better ocular hypotensive effects with esterification of the prostaglandin carboxylic acid group, which is the basis of the prodrug principle (Kerstetter et al, 1988). Esterification of the carboxylic acid reduces polarity and facilitates penetration of the prodrug through biological lipid membranes. The prodrug is then converted to free acids to activate the specific FP receptors once it crosses the corneal...
epithelium in the specific direction known as orthrorectified transport or the slow release system, which is ideal for chronic therapy in glaucoma and minimizes unwanted ocular and systemic side effects (Figure 1.2).

Fig. 1.2. Chemical structure of major topical prostaglandin analogue pro-drugs and their hydrolyzed free acids.

After more than 2 decades in search of a topical prostaglandin with an acceptable therapeutic index, Unoprostone (13, 14-dihydro-15-keto metabolite of PGF$_{2\alpha}$) with the trade name of Rescula (Ciba Vision, Duluth GA) was made commercially available in Japan. The drug failed to gain popularity worldwide due to lack of efficacy and the requirement for twice-daily administration. In 1996, latanoprost (13, 14-dihydro-17-phenyl-18, 19, 20-trinor-PGF$_{2\alpha}$-isopropyl ester) was marketed as Xalatan (Pfizer Inc, New York) and gained approval worldwide. Later, travoprost (Travatan; Alcon) and bimatoprost (Lumigan; Allergan) were introduced. Unlike latanoprost and travoprost, bimatoprost has been controversy known as prostamide owing to the presence of a C1 ethyl amide group that activates different receptors. However, topical prostaglandin analogues are believed to achieve pressure-lowering effects by increasing uveoscleral outflow without any effect on aqueous humour production (Toris et al, 1993). However, their effect on the trabecular meshwork remains unclear (Oh et al, 2006; Johnson et al, 2010). There was no statistically significant difference in efficacy between the 3 commercially available topical prostaglandin analogues but there was a reported borderline increased incidence of ocular hyperaemia with bimatoprost (van...
Bimatoprost has the edge in effectiveness but with slightly more pronounced side effects (Cracknell and Grierson, 2009). Topical prostaglandin analogues have changed the paradigm of glaucoma management, most notably with the declining rate of glaucoma surgeries in the late 1990s (Bateman et al, 2002). Currently, due to their efficacy and better tolerability, topical prostaglandin analogues are replacing topical timolol as the first-line drug of choice in glaucoma management (Holmstrom et al, 2006). It is amazing that low lipid solubility drugs in low concentrations can achieve such an impact in glaucoma management.

3.1 Topical latanoprost 0.005%

Topical prostaglandin analogue PhXA34 (13, 14-dihydro-17-phenyl-18, 19, 20-trinor-PGF₂α-isopropyl ester) known as latanoprost, differs from the naturally occurring PGF₂α, where C18 to C20 have been substituted by a benzene ring, the double bond between C13 and C14 has been saturated, and the carboxylic acid moiety on C1 has been esterified with isopropanol (Figure 1.7). The molecular weight of latanoprost is 432.6 and the hydrolysed compound (free acid) is 390.5 (Stjernschantz and Alm, 1996). The octanol-water partition coefficient is 4.3 at pH 7.4, with poor solubility in water. It is available as a colourless to slightly yellow oil solution in 0.005% concentration (50µg/ mL) preserved with 0.02% benzalkonium chloride. It is commercially available in 5 mL plastic bottles (2.5 mL latanoprost solution), which requires refrigeration to maintain a temperature of 2 to 8°C for unopened bottles. The recommendation for refrigeration was made based on experimental finding in the laboratory. There was 10% degradation after extreme exposure to 50°C for 198 hours (Morgan et al, 2001). In clinical practice, it is safe to transport and store at room temperature without reducing the effectiveness of the drug (Novak and Evans, 2001; Varma et al, 2006). Latanoprost can be prescribed as either evening or morning once-daily dosing but evening dosing is more efficacious (Alm and Stjernschantz, 1995).

Latanoprost is a selective FP receptor agonist with marginal spillover effect on other prostanoid receptors, resulting in fewer unwanted side effects. Naturally occurring PGF₂α has greater affinity than latanoprost for the FP receptor but also interacts with other prostaglandin receptors, which is partly responsible for side effects such as iritis and conjunctival hyperaemia (Alm and Stjernschantz, 1997). As a prodrug, it is relatively inactive until the hydrolyzation of the isopropyl ester to free acid in the cornea and plasma. Latanoprost in free acid form is measurable in the aqueous humour within 4 hours of instillation. Approximately 1% of topically applied latanoprost is absorbed into the eye, the majority being absorbed into the systemic circulation through either conjunctiva vessels and nasal mucosa or gastrointestinal tract absorption. The peak concentration is reached about 2 hours after topical instillation with the distribution volume of 0.16 ± 0.02 L/kg in humans (Sjöquist and Stjernschantz, 2002). The half-life of free acid in human plasma is about 17 minutes. Plasma levels of latanoprost acid were below the detection limit in patients treated with latanoprost for a year. Latanoprost is metabolized by β-oxidation in the liver; it is not metabolized in the cornea and is mainly excreted in the urine (88–98%).

Although the exact mechanism of action of latanoprost is still uncertain, FP receptor plays essential role and FP receptor-deficient mice do not exhibit any pressure-lowering effect (Ota et al, 2005; Crowston et al, 2004). Aqueous humour production is not significantly affected by latanoprost but the most consistent finding is a substantial increase in uveoscleral (pressure-insensitive) outflow; a less consistent finding is the role in trabecular (pressure-sensitive) outflow capacity (Toris et al, 2008; Lim et al, 2008; Johnson et al, 2010).
There are 3 potential mechanisms by which latanoprost could increase uveoscleral drainage. These include: (1) Remodelling of extracellular matrix of the ciliary muscle and sclera causing permeability changes, (2) widening of the connective tissue-filled spaces among the ciliary muscle bundles, which may be caused by relaxation of the ciliary muscle and (3) changes in the shape of ciliary muscle cells as a result of altered actin and vinculin localization (Toris et al, 2008; Lindsey et al, 1997). The remodelling of extracellular matrix is believed to be responsible for sustaining the long-term pressure-lowering effect (Johnson et al, 2010).

Ciliary muscle relaxation is believed to be responsible for the initial reduction of IOP but the effect is not prominent in latanoprost. Remodelling of the extracellular matrix within the ciliary muscle and sclera is the most thoroughly understood and most accepted mechanism. Latanoprost stimulates induction of Matrix Metallo-proteinases (MMP) 1, 2, and 3 that cause dissolution of collagen types I and III within the connective tissue-filled spaces between the outer longitudinal muscles (Lütjen-Drecoll and Tamm, 1988). Animal experimental studies showed evidence of changes in ciliary muscle; the tissue spaces of the ciliary muscle were enlarged and organized into tube-like spaces covered by endothelial-like cells with close basement membrane contact, and contained myelinated nerve fibre bundles that resembled a lymphatic system in the choroid (Krebs and Krebs, 1988; Richter et al, 2003).

Latanoprost induced MMP 3, 9, 17, and TIMP 3, and down-regulated MMP 1, 2, 12, 14, 15, 16, and TIMP 4. Latanoprost acid induced concentration-dependent increases in MMP 1, 3, and 9 gene transcriptions and a concentration- and time-dependent increase in TIMP 1 but not TIMP 2 mRNA and protein (Anthony et al, 2002). Cyclooxygenase (COX)-2 is also believed to play a role in the pressure-lowering effect of latanoprost (Sales et al, 2008). The mechanism of latanoprost-induced MMP secretion is through protein kinase C and extracellular signal-regulated protein kinase 1/2-dependent pathways (Chen et al, 2001). Mitogen-activated protein kinase and tumour necrosis factor α-dependent signalling pathways may also be involved (Sardar et al, 2000). The vasodilatation effect of latanoprost, although minimal, is also postulated to play a role in facilitating uveoscleral outflow. Although increases aqueous outflow through non-conventional pathways seems to be responsible for the pressure-lowering effect of latanoprost, there are ongoing studies providing evidence of the possible role of trabecular meshwork outflow (Oh et al, 2006).

In spite of uncertainty in the mechanism of latanoprost action, latanoprost is a clinically proven efficacious topical anti-glaucoma drug. Its effectiveness has been observed in many populations. Hedman and Larsson (2002), based on mean diurnal IOP reduction, found that latanoprost is more effective than timolol in 8 different populations with greater reduction among Mexican and Asian populations. A meta-analysis involving 1256 glaucoma patients found that latanoprost is superior to timolol in long-term IOP control (Zhang et al, 2001). Latanoprost has the advantage of achieving IOP reduction during both day and night while timolol has a minimal effect on nocturnal IOP (Larsson et al, 2002). In a long-term study, latanoprost sustained meaningful IOP reduction (Hedman et al, 2002). Latanoprost is not only effective in OAG but also in angle-closure glaucoma (Chew et al, 2004). In spite of its higher therapeutic index, there was a reported 18–25% non-responder rate (Scherer, 2002; Cheong et al, 2008; Camras and Hedmann, 2003). The definition of a responder varies according the predetermined cut-off point. Based on the US latanoprost study group, a greater proportion of patients classified as non-responders on any particular visit were responders on all other visits if treated with latanoprost rather than timolol (Camras and Hedmann, 2003). Among PG analogues, bimatoprost seems to be slightly superior in
reducing pressure but not without a price (van der Valk et al, 2005). Bimatoprost has a higher incidence of conjunctival hyperaemia. Although PGF\(_2\alpha\) is responsible for stimulating bronchial hyper-responsiveness, respiratory impairment induced by latanoprost has not been reported (Hedner et al, 1997). Short half-life and rapid clearance of the active latanoprost acid minimizes unwanted systemic side effects (Sjöquist and Stjernschantz, 2002). Furthermore, latanoprost free acids that enter the systemic circulation do not permeate tight-junction cell membrane barriers such as the blood-brain barrier, minimizing the potential for central nervous system side effects. However, some nonspecific systemic side effects such as headache, flulike syndromes, upper respiratory tract infections, and musculoskeletal pain have been reported (Alm et al, 1995).

Latanoprost-induced ocular side effects are a major concern. Conjunctival hyperaemia is a common side effect with the incidence range between 5 to 15% (Stewart et al, 2003; Walters et al, 2004). The incidence is much higher in travoprost and bimatoprost (Honrubia et al, 2009; Walters et al, 2004). Conjunctival hyperaemia is generally mild and transient, and commonly develops within 1 month of therapy initiation. Vasodilation induced by prostaglandin promotes the release of nitric oxide that may be responsible for conjunctival hyperaemia (Alm et al, 2008). The saturated double bond in C13 and C14 of latanoprost is partly responsible (Resul and Stjernschantz, 1993). Ocular irritation, burning sensation, and dry eye are also reported (Stewart et al, 2003). However, the most intriguing side effect is the ability of latanoprost to induce pigmentation in the iris, eyelid, and eyelashes. Latanoprost-induced iris darkening (LIID) was found in higher frequency in heterogeneous hazel irises and homogeneous gray and blue irises are less likely to develop LIID in Caucasians (Alm et al, 2008). Japanese and South East Asians, in spite of having homogeneous dark brown irises, were more likely to develop LIID (Chiba et al, 2004; Chou et al, 2005). During phase III of a latanoprost study, latanoprost was postulated to have the ability to promote iris melanocyte proliferation (Stjernschantz et al, 2002). However, there was no evidence of increases melanogenesis in tissue culture studies (Kashiwagi et al, 2002; Drago et al, 1999). Histopathological and morphometric studies found evidence of increased iris melanocytes in the stroma and redistribution of the melanocytes to the anterior iris stroma without a net increase in number (Cracknell and Gierson, 2009; Cracknell et al, 2003; Albert et al, 2008). LIID is irreversible and causes cosmetic concerns, especially when it occurs in one eye, but has no incapacitating visual side effects. Hyperpigmentation, elongation, and thickening of the eyelashes (hypertrichosis) may cause the lashes to touch the spectacles or cause difficulty in topical drug instillation but is never a major concern (Johnstone, 1997; Shaikh and Bodla, 2006). Unlike LIID, hypertrichosis is reversible and disappears several weeks after discontinuation of treatment. Peri-ocular hyperpigmentation is also reported and is most likely due to accidental spillover during drug administration (Herndon et al, 2003). Similar to hypertrichosis, the reversal of ocular hyperpigmentation was also reported even without discontinuation of treatment (Sharpe et al, 2007). There were also reported cases of hypo-pigmentation (Herndon et al, 2003).

Disruption of the blood-aqueous barrier and posterior lens releases inflammatory mediators causes cystoids macular oedema (CME) following latanoprost treatment (Miyake et al, 1999). Latanoprost-induced CME may cause visual impairment but the incidence is uncommon in comparison to the frequency of pigmentation-induced side effects (Warwar et al, 1998). Prostaglandin at higher concentrations acts as an inflammatory mediator and anterior uveitis was reported following latanoprost treatment (Warwar et al, 1998).
Reactivation of herpes simplex keratitis has been reported in 3 patients with a history of herpes simplex infection (Wand et al, 1999). In patients with a high risk of CME, anterior uveitis, and past history of herpes simplex, latanoprost is not recommended for glaucoma treatment.

### 3.2 Topical Travoprost

Travoprost (AL-6221) is an isopropyl ester of the (+) enantiomer of fluprostanol and chemically known as isopropyl (z)-7-[IR, 2R, 3R, 5S]-3, 5-dihydroxy-2-[ (IE, 3R)-3-hydroxy-4-[ (a, a-tri-fluoro-m-tolyl) oxy]-1-butenyl] cyclopentyl]-5-heptenoate. Similar to latanoprost, travaprost is a prodrug that acts on FP receptor (Hellberg et al, 2001). It is believed through unknown mechanism, travaprost increase outflow through mainly unconventional pathway with some effect on conventional pathway (Torris et al, 2008). Unlike latanoprost, travaprost provides prolong pressure lowering effect up to 40 hours post single instillation (Fellman et al, 2002).

Travoprost is reported to provide up to 28% pressure reduction from baseline, which is almost similar to latanoprost and significantly superior to timolol (Netland et al, 2001). However, travoprost provides lesser additional IOP reduction than bimatoprost in patients previously treated with latanoprost (Kammer et al, 2010). Similar to latanoprost, travaprost is efficacious in various type of glaucoma as monotherapy, adjunctive, replacement therapy and in fixed combination (Cheselita D, 2007; Orengo et al, 2001).

A retrospective metanalysis study found that travoprost is superior to both latanoprost and timolol in African derived patients (Netland et al, 2003). Halpern et al (2002) found that travoprost not only more efficacious to timolol and latanoprost but also less likely to cause visual field progression in African derived patients. A prospective randomized study was conducted to study the potential of racial influence on efficacy of prostaglandin analogs, found no significant different between races and different type prostaglandin analogs (Birt et al, 2010). However, this study was hampered by small sample size.

Conjunctival hyperaemia is the most common ocular side effect. The incidence and intensity was reported to be higher and more severe than in patients treated with latanoprost (Parmaksiz et al, 2006; Li N et al 2006). Prostaglandin induced iridial pigmentation (PIIP) is another common ocular side effect. Travaprost is a safe drug with no reported systemic side effect.

### 3.3 Topical Bimatoprost

Unlike latanoprost and travaprost, bimatoprost has ethyl amide group in the carbon-1 position (Cantor, 2001). Chemical structure of bimatoprost is pharmacologically similar to prostaglandin F$_{2a}$ ethanolamide, better known as prostandides. Prostandides are biosynthesized from endocannabinoid anandamide by enzyme cyclo-oxygenase 2 (COX-2). Bimatoprost is a synthetic endogenous prostandides (Woodward et al, 2001). Bimatoprost acts on prostandide-sensitive receptor with minimal or no effect on prostaglandin F receptors. Bimatoprost as prostandide mimetic is fatty acid amide, which differs from fatty acid of prostaglandin (Woodward et al, 2003). Another striking difference from latanoprost and travaprost, it is not a prodrug (Woodward et al, 2001). There is no evidence of measurable free acid detected at the site of action in the eye. Therefore, hydrolysis is not required for bimatoprost to exert its pharmacological action. Latanoprost and travaprost require hydrolysis to free acid to act on FP receptor as agonist.
Bimatoprost produces more pronounced and prolonged pressure lowering effect. It is effective as monotherapy, adjunctive therapy, and replacement therapy and also as fixed combination with timolol. It was found to provide 35% pressure reduction in primary angle closure patients with 360° of posterior synechiae post ineffective laser peripheral iridotomy (Vyas et al, 2011). It is believed that bimatoprost acts on pressure sensitive and pressure insensitive outflow pathway (Brubaker et al, 2001). Latanoprost has minimal effect on pressure sensitive pathway; trabecular meshwork. Long term treatment of bimatoprost in animal experimental study has shown remodelling in uveoscleral as well as trabecular meshwork pathway. Similar to other prostaglandin analogs, bimatoprost produced significant better IOP reduction compared to timolol. In comparing between prostaglandin analogs, bimatoprost was found slightly superior to travaprost and latanoprost in pressure lowering medications. In addition, bimatoprost provides more constant IOP reduction and less fluctuation as compared to latanoprost and Timolon XE (Walters et al, 2004; Konstas et al, 2005). Fluctuation of IOP may cause further detrimental effect especially in already compromised optic nerve head. Bimatoprost has the edge for pressure lowering effect but reported higher incidence of conjunctival hyperaemia. The incidence of conjunctival hyperaemia was reported in 15-45% in patients treated with bimatoprost as monotherapy (Feldman, 2003). The most recent meta-analysis of 13 randomized control trials in 2222 glaucoma patients found significant higher incidence of conjunctival hyperaemia with bimatoprost compared to latanoprost (Honrubia et al, 2009). However, there is evidence to suggest that conjunctival hyperaemia decreases with time (Arcieri et al, 2005). Other ocular side effects such as prostaglandin induced iridial pigmentation (PIIP), uveitis and cystoids macular edema are almost similar with other topical prostaglandin analogs.

4. Carbonic anhydrase inhibitors

Carbonic anhydrase inhibitor (CAI) was discovered by Becker in 1954 after several breakthrough findings. Bicarbonate was found to be an essential component of aqueous humour production and carbonic anhydrase enzyme was found in rabbit ciliary processes. Acetazolamide, a CAI, has gained popularity as an effective systemic anti-glaucoma medication when given orally or parenterally. Discontinuation of CAI is typically prompted by the occurrence of side effects such as general malaise, fatigue, depression, loss of appetite, weight loss, paraesthesia, and gastrointestinal disturbance. Intolerability to systemic CAI has been reported in 30% to 80% of patients, and is not ideal for long-term administration. In addition, devastating systemic side effects such as metabolic acidosis, hypokalaemia, and blood dyscrasia limit its usefulness. Haematological reactions such as agranulocytosis, aplastic anaemia, thrombocytopenia and neutropenia have also been reported (Fraunfelder et al, 1985). However, 40 years passed before the introduction of topical CAIs dorzolamide and brinzolamide, which have fewer unwanted extra-ocular side effects. The delay was due to failure to achieve 100% inhibition of carbonic anhydrase-II (CA-II), which is associated with poor ocular penetration. CA-II is an isoenzyme that plays an important role in the production of aqueous humour. The addition of an alkylamino side group improved the ocular penetration of topical CAI. Topical dorzolamide 2% or brinzolamide 1% monotherapy administered 2 or 3 times daily provides pressure reduction ranging from 21.8% to 26.2% (Lippa et al, 1991; Lippa et al, 1992). Three applications per day provide better overall ocular hypotensive effect (Lippa et al, 1992). The combination of topical dorzolamide and oral acetazolamide failed to
Pressure Lowering Medications

demonstrate an additive effect (Rosenberg et al, 1998); therefore, combination therapy is not recommended as it may increase the risk of unwanted systemic side effects. Topical dorzolamide also provided further IOP reduction as adjunctive therapy with topical timolol, especially in gel solution (Adamsons et al, 1998a). The adjunctive effect of dorzolamide with topical timolol was similar to that of topical pilocarpine (4 times daily) but with better tolerability and compliance (Sthralman et al, 1996; Adamsons et al, 1998b). A fixed combination of 2% dorzolamide and 0.5% timolol, and 1% brinzolamide and 0.5% timolol was recently introduced; it is more efficacious than individual drug therapy and promotes better compliance (Boyle et al, 1998; Clineschmidt et al, 1998). Stinging, burning, or foreign body sensation and blurred vision are the most common ocular side effects. Others include superficial punctate keratitis, lid or conjunctival allergies, corneal oedema, and headache. Due to the effect of topical CAI on endothelium pump function, corneal edema has been reported especially in patient with underlying cornea problem such as guttata (Mathias et al, 2007). In fact, irreversible corneal decompensation following topical dorzolamide therapy has also been reported (Konoval et al, 1999). Systemic side effects similar to those associated with oral CAI have not been reported with dorzolamide, although bitter taste is reported.

5. Topical adrenergic agonists

Topical adrenergic agonists were introduced in the early 1920s when Hamburger (1923) applied topical epinephrine to patients with increased IOP. Epinephrine is a direct acting sympathomimetic amine with a combination of α- and β-adrenergic receptor-stimulating activities. The exact mechanism of the pressure-lowering effect of epinephrine is not fully understood. Based on evidence from fluorophotometry, tonography, and tonometry, epinephrine is believed to increase both conventional and unconventional outflow but certain observers found that uveoscleral outflow exceeded trabecular outflow (Weekers et al, 1955; Townsend and Brubaker, 1980; Schenker et al, 1981). Epinephrine may also stimulate aqueous humour production (Nagataki and Brubaker, 1981). β-receptor stimulation is believed to occur through a cyclic AMP (cAMP)-dependent mechanism, as demonstrated in animal studies and an in vitro human eye outflow pathway perfusion model (Neufeld et al, 1979, Boas et al, 1981). Unlike pilocarpine, epinephrine induced slight mydriasis, conjunctival decongestion, and pressure reduction in glaucoma and ocular hypertensive patients. The effect of vasoconstriction and mydriasis is temporary; lasting only 2 to 12 hours, but the IOP reduction lasts longer. The effect on IOP is biphasic with transient IOP elevation followed by a hypotensive period. Epinephrine is no longer in use in many centres due to its low therapeutic index and its devastating ocular and systemic side effects. It was used as an additive or adjunctive drug at 0.25% to 2% concentrations. Deposition of the epinephrine in ocular tissue including choroids, retina, and optic nerve, especially in aphakic patients is common (Kramer, 1980). In fact, it may also deposit in the heart and spleen following topical instillation, especially without punctual occlusion, and is almost comparable to parenteral administration. Prolonged use may result in localised pigment deposition (believed to contain epinephrine oxidation products such as adrenochrome) particularly in the palpebral conjunctiva and occasionally in the lid margin and cornea (Fong et al, 1993). Epinephrine maculopathy characterised by macular oedema, vascular spasm, and small cysts or fine haemorrhages may occur in aphakic patients (Michels and Maumenee, 1975). Fortunately, it is reversible upon treatment withdrawal but may cause alarming visual symptoms in affected patients. It
is also not recommended for glaucoma patients wearing soft contact lenses due to deposition of adrenochrome during treatment initiation. Systemic sympathomimetic effects such as palpitation, tachycardia, premature ventricular contractions, severe headache, and even hypertensive crisis may also occur (Ballin et al, 1966). In order to promote tolerability and reduce side effects, an epinephrine analogue was introduced as dipivefrin. Dipivefrin was the first pro-drug commercially available in ophthalmic practice (Mandell and Podos, 1977). The lower concentration 0.1% of Dipivefrin is sufficient to achieve similar ocular hypotensive effects as 2% epinephrine with fewer ocular and systemic side effects.

Selective α2-adrenoreceptor agonists are replacing topical epinephrine; Apraclonidine and brimonidine have higher therapeutic indexes and fewer unwanted side effect. Apraclonidine, a relatively selective α2-adrenoreceptor agonist, is chemically related to clonidine. Therefore, it reduces IOP and has a systemic hypotensive effect. Apraclonidine reduces IOP by suppressing aqueous humour production and enhancing uveoscleral outflow (Gharagozloo et al, 1988). It has a minimal effect on ocular blood flow because of its limited activity at the α1 receptor. It is commercially available in 0.5% and 1.0% concentrations. Although 1.0% apraclonidine produces slightly better IOP reduction (up to 31%) than the 0.5% solution (26%), the difference is statistically insignificant (Abrams et al, 1989). However, most patients responded with at least 20% IOP reduction from baseline, making it an excellent additive medication (Toris et al, 1995; Araujo et al, 1995; Gross et al, 1997). In fact, apraclonidine 0.5% 3 times a day for 90 days provides additional IOP reduction in glaucoma patients treated with concomitant timolol (Stewart et al, 1996). Through its ability to protect the blood-aqueous humour barrier, apraclonidine 1.0% is used to prevent a spike in IOP after cataract surgery or anterior segment laser surgery and as prophylaxis for post-cycloplegic IOP and for short-term IOP control prior to filtration surgery (Robin, 1989; Mori and Araie, 1992; Arai and Kiyoshi, 1993). Apraclonidine is not affected by the amount of ocular melanin. However, the effectiveness of apraclonidine is short-lived. The occurrence of tachyphylaxis and ocular allergy reduce its attractiveness for long-term treatment (Butler et al, 1995; Araoujo et al, 1995).

As a relatively selective α-adrenoreceptor agonist, apraclonidine also stimulates the α1 receptor. Stimulation of the α1-adrenoreceptor is responsible for conjunctival hyperaemia, eyelid retraction, and a mild mydriatic effect (less than 1 mm). Ocular allergy is rare in short-term treatment but poses a major concern that warrants discontinuation in long-term therapy. Apraclonidine is also associated with dry mouth and dry nose, which limits its systemic absorption and reduces systemic side effect. The activity of brimonidine tartrate is similar to that of apraclonidine. Animal studies have shown that brimonidine may possess neuroprotective properties. However, unlike apraclonidine, brimonidine tartrate is a highly selective α2-adrenoreceptor agonist with 30 times more selectivity than apraclonidine and reduced risk of ocular allergy. In fact, there is no evidence of cross-reactivity in patients allergic to apraclonidine who were switched to brimonidine (William et al, 2000; Shin DH et al, 1999). Thus, prescribing brimonidine in patients allergic to apraclonidine is safe and effective (Shin DH et al, 1999). Brimonidine also binds to ocular melanin, which acts as drug reservoir, providing a slow-release effect. The pressure-lowering effect of brimonidine was almost equal to topical timolol in a short-term study.

6. Pilocarpine

Topical pilocarpine was the first topical pressure-lowering drug used in clinical practice. Pilocarpine, a direct-acting cholinergic agonist or parasympathomimetic, was introduced in
An alkaloid derivative of natural plants, pilocarpine acts directly at neuro-effector junctions of the iris sphincter muscle and ciliary body causing pupillary constriction (miosis), spasm of accommodation, and reduction of IOP (Taylor, 1990). Although the precise mechanism of the pilocarpine effect has not been established, the most widely accepted explanation is that direct stimulation of the longitudinal muscle of the ciliary body causes widening of the trabecular spaces, facilitating aqueous humour outflow (Erikson and Schroeder, 2000). It is available in ophthalmic solution 0.5% to 10% and prescribed for application 4 times daily. There is an increasing hypotensive effect with increasing concentrations up to 4% in long-term therapy. Concentrations exceeding 4% provide minimal additional benefit. Due to its effect on ocular melanin, higher concentrations of pilocarpine are needed in darkly pigmented patients to achieve the same effect as in those with lighter-coloured irises (Harris and Galin, 1971). A sustained-release, membrane-bound drug delivery system (Ocusert) is available, which delivers pilocarpine at a controlled rate of 20–40 µg/hour. A 4% ophthalmic gel is also available.

IOP reduction up to 15% from baseline was observed in many types of glaucoma including POAG, PAC, PACG, and secondary glaucoma. The ability of pilocarpine to reduce or break the iridotrabecular contact in acute attacks of PAC is believed to be due to its miotic action. Its effectiveness in facilitating outflow has helped to sustain pilocarpine as a viable medication in glaucoma therapy. However, if the IOP exceeds 60 mmHg, pilocarpine has a limited effect on the iris sphincter, presumably because of ischaemia. It is widely used to stretch the iris in preparation for laser iridotomy and iridoplasty. Pilocarpine provides further IOP reduction in combination with topical beta blockers, CAI, adrenergic agonist and latanoprost (Airaksinen et al, 1987; Fristom and Nielson, 1993).

The diminishing popularity of pilocarpine is partly due to the frequency of dosage required to achieve optimal results and to ocular side effects. The most troublesome ocular side effect is accommodative spasm, which may last for 2 to 3 hours and is frequently intolerable, especially in individuals less than 40 years old (Zimmerman, 1981). However, due to the aging process, a lesser effect on ciliary muscle contractility is seen in older patients. The miotic effect of pilocarpine can cause visual incapacitation and is unwelcome in patients with nuclear sclerotic and posterior sub-capsular cataract. Furthermore, long-term use of pilocarpine may hasten cataract development (Zimmerman and Wheeler, 1982). Paradoxically, although pilocarpine is used to break the iridotrabecular contact in PAC cases, there are reported cases of pupillary block induced by pilocarpine, which usually occurs in patients with narrow angles who have advancing cataract (Van Burskirk, 1982; Ritch, 1996). Other side effects include retinal detachment, allergic blepharoconjunctivitis, band keratopathy, iris cyst, and lid myokymia. Adverse systemic reactions to Ocusert are rare but may occur in patients with acute PAC or inadvertent drug leakage (Kushnick et al, 1996). Headache, nausea, vomiting, diaphoresis, and weakness are possible systemic side effects and can be easily confused with symptoms of acute PAC (Zimmerman and Wheeler, 1982). Other systemic side effects include increased salivation and lacrimation, diarrhoea, bronchiolar spasm, pulmonary oedema, systemic hypotension, and bradycardia (Zimmerman and Wheeler, 1982).

### 7. Fixed combination

Pressure lowering drugs therapy requires patient’s compliance to ensure the maximum effectiveness of the drugs especially in long term administration and even more challenging
in asymptomatic disease at the early stage glaucoma. The term of compliance is deemed inappropriate. Instead, adherence and persistence provide better description of patient’s behaviour toward medication instillation. Adherence is a measure of the degree of patient obeying pharmacotherapy instruction over a defined period of time (Schwartz and Quigley, 2008). For example, if topical timolol is prescribed twice a day for a month but the patient only instilled 40 times, his/her adherence is 66%. Persistence is a measure of time to discontinuation. Accurate assessment of adherence and persistence is quite a challenge especially when most patients routinely overestimate their adherence (Friedman et al, 2008; Friedman et al, 2007). Poor adherence and persistence is associated with cost of the drug, tolerability, difficulty in instillation, lack of education, forgetfulness, denial, schedule and travel issues (Tsai et al, 2003; Friedman et al, 2008). ‘White coat adherence’ is another issue, in which patients are at their best adherence during 5 days prior to the follow up appointment; follow by a declining pattern until near to the next follow up (Feinstein, 1990). Frequency of dosing and complexity of the regimen also play important role. Poorer adherence is observed in those receiving adjunctive treatment (Nordstrom et al, 2005). Patients’ understanding of the importance of taking medication, their satisfaction with the drug, tolerability and cost is reflected by persistency. Persistence is not doing any better, ranging from 20% to 67% (Dasgupta et al, 2002; Spooner, 2002) and differs according to the class of pressure lowering drugs. Latanoprost, a prostaglandin analog has demonstrated better persistency compared to other drugs (Reardon et al, 2004; Schwartz et al, 2004). Thus, recently there is a sprouting of fixed combination pressure lowering treatment such as prostaglandin-beta blocker, carbonic anhydrase inhibitor-beta blocker and pilocarpine-beta blocker, which aim to improve adherence and persistence.

Fixed combination therapy is based on the concept that different group of drugs act on different site of receptors or enzymes. It is postulated to provide additional pressure reduction of at least 15% from non-fixed combination. However, the pressure reduction with fixed combination is usually less than the sum of both drugs (Philip and Luc, 2000). The earliest fixed combination introduced in glaucoma management was beta-blockers and pilocarpine; 0.5% timolol and 2% pilocarpine, 0.5% timolol and 4% pilocarpine, and 0.1% metipranolol and 2% pilocarpine (Table 1.3). Pressure lowering effect of these fixed combination were found to be similar to the non-fixed combination or concomitant therapy (Maclure et al, 1989). The most important success in fixed combination of beta blockers and pilocarpine is convenience and reduction of instillation frequency of pilocarpine (Puustjärvi and Repo, 1992).

Topical beta-blockers have been the most reliable pressure lowering drug for many decades. Currently, beta blockers not only used as the gold standard for comparative studies with other medications but also the most popular for fixed combination therapy. The success of fixed combination of beta blockers and pilocarpine has later inspired the drug manufacturers to produce other fixed combination (table 1.3). Fixed combination therapy provides additional option for ophthalmologists but the actual impact in clinical practice is not well established.

Comparison of the fixed combination therapy with monotherapy of individual drug has shown promising result. Fixed combination of 0.5% timolol and 2% dorzolamide provides an additional 13 to 20% pressure reduction at peak and 5 to 14% at through compared to timolol monotherapy (Strohmaier et al, 1998; Boyle et al, 1998). Fixed combination of 0.5% timolol and 0.2% brimonidine has also shown significantly better pressure lowering effect of
4.4 to 7.6 mmHg as compared to brimonidine and timolol individually. Most important advantage of fixed combination timolol-brimonidine is lesser side effect compared to brimonidine monotherapy but increase compared to timolol monotherapy (Mark et al, 2006).

<table>
<thead>
<tr>
<th>Brand name</th>
<th>Constituents</th>
<th>Preservatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timpilo-2®</td>
<td>0.5% Timolol maleate + 2% Pilocarpine hydrochloride</td>
<td>BAK</td>
</tr>
<tr>
<td>Timpilo-4®</td>
<td>0.5% Timolol maleate + 4% Pilocarpine hydrochloride</td>
<td>BAK</td>
</tr>
<tr>
<td>Normoglaucon®</td>
<td>0.1% Metipronalol + 2% Pilocarpine hydrochloride</td>
<td>BAK</td>
</tr>
<tr>
<td>Cosopt®</td>
<td>0.5% Timolol maleate + 2% Dorzolamide hydrochloride</td>
<td>BAK</td>
</tr>
<tr>
<td>Azarga®</td>
<td>0.5% Timolol maleate + 1% Brinzolamide</td>
<td>BAK</td>
</tr>
<tr>
<td>Combigan®</td>
<td>0.5% Timolol maleate + 0.2% Brimonidine tartrate</td>
<td>BAK</td>
</tr>
<tr>
<td>Duo Trav®</td>
<td>0.5% Timolol maleate + 0.004% Travaprost</td>
<td>BAK</td>
</tr>
<tr>
<td>Ganfort®</td>
<td>0.5% Timolol maleate + 0.03% Bimatoprost</td>
<td>BAK</td>
</tr>
<tr>
<td>Xalacom®</td>
<td>0.5% Timolol maleate + 0.005% Latanoprost</td>
<td>BAK</td>
</tr>
</tbody>
</table>

BAK: benzalkonium chloride

Table 1.3: Fixed combination of pressure lowering drugs

It is seem unfair to compare the fixed combination therapy with monotherapy treatment. Fixed combination is basically mixing the two drugs together, how the individual constituent of the drugs is adjusted or mixed is not known. The possibility of drug-drug interaction and drug-preservative interaction is not well established. Majority of clinical data available are on the comparison between fixed combination and concomitant therapy (Khouri et al, 2007). The efficacy of fixed combination and concomitant therapy is controversial. There are evidences that suggest the superiority of fixed combination (Diestelhorst and Larsson, 2004; Schuman et al, 2005). On the other hand, there are adequate evidences to suggest otherwise (Strohmaier et al, 1998; Diestelhorst and Larsson, 2006; Hughes et al, 2005). However, there are many factors such time of IOP measurement, time of instillation, diurnal variation and the possibility of wash out period that are not taken into consideration and lead to over or underestimation (Khouri et al, 2007).

A systematic review involving seven randomized controlled trials on various fixed combination with 0.5% timolol; travaprost, latanoprost, dorzolamide and brimonidine found that the concomitant treatment with individual drug has the edge in efficacy. However, the difference failed to exert pre-determined non-inferiority measure of ≤1.5mmHg upper confidence limit (Cox et al, 2008). Similar outcome is also noted in another systematic review and metanalysis of 29 studies involving fixed combination of prostaglandin analogs and timolol (Webers et al, 2010). Fixed combination therapy has advantages over multiple drop and multiple bottle therapy, improving patient convenience and adherence and perhaps more economical in a long run. However, the efficacy is still doubtful especially in advance cases when 1mmHg pressure reduction is meaningful. Prescription of fixed combination therapy needs to be tailored and customized according to patients.

8. The impact of topical pressure lowering drugs on glaucoma surgery

Apart from adherence and persistence problem, topical pressure lowering drug may potentially induced subclinical conjunctival inflammation. Subclinical conjunctival
inflammation is believed to be associated to the success of trabeculectomy. Long term and multiple treatments of topical pressure lowering drugs are believed to induce subclinical inflammation of the conjunctival that may induce excessive scarring of the bleb and eventually responsible for trabeculectomy failure (Sherwood et al, 1989; Broadway et al, 1994a; Broadway et al, 1994b). The histological evidence is inconsistent. Although there is evidence that suggest pressure lowering drugs induced mark increased in inflammatory markers and macrophages, there is also evidence against it (Sherwood et al, 1989; Broadway et al, 1994a; Baun et al, 1995; Liza-Sharmini et al, 2007). In addition, it is still not clear whether the active ingredient or the preservative exerts more detrimental effect. Benzalkonium chloride, the most common preservative used in topical antiglaucoma medication has been implicated to cause elevation of inflammatory markers in tissue culture and animal models (De Saint Jean et al, 1999; Debbasch et al, 2001; Becquet et al, 1998). Preservative free timolol was found to express less interleukins and inflammatory markers (Baudouin et al, 2004). On the other hand, sympathomimetics has been postulated to induce significant conjunctival cell profile changes and associated with poorer trabeculectomy outcome (Broadway et al, 1994a). In fact, discontinuation of sympathomimetics and steroid treatment has been proven to reverse this silent effect of pressure lowering medication (Broadway et al, 1996). Medical treatment versus surgical intervention as the first line management of glaucoma is still debatable.

9. References


Chesilita D 2007, "Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients", Ophthalmologica, vol. 51, pp. 81-86.


Fellman RL, S. E. R. M. e. a. f. T. S. G. 2002, "Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6 month, masked, multicentre trial", Ophthalmology, vol. 109, pp. 998-1008.


Frohman RL, S. E. R. M. e. a. 2002, "Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6 month, masked, multicentre trial", Ophthalmology, vol. 109, pp. 998-1008.


Hughes BA, B. J. C. R. e. a. 2005, “A three-month, multicentre, double masked study of the safety and efficacy of Travaprost 0.004%/Timolol 0.5% ophthalmic solution compared to Travaprost 0.004% ophthalmic solution and Timolol 0.5% dosed concomitantly in subjects with open angle or ocular hypertension", *J Glaucoma*, vol. 14, pp. 392-399.


Konstas AG, K. J. L. N. e. a. 2005, "Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients", *Ophthalmology*, vol. 112, pp. 262-266.


www.intechopen.com


Maclure GM, V. R. S. T. e. a. 1989, "Effect on the 24 hour diurnal curve of intraocular pressure of a fixed ratio combination of timolol 0.5% and pilocarpine 2% in patients not controlled on timolol 0.5%", Br J Ophthalmol, vol. 73, pp. 827-831.


Mark BS, R. C. C. C. e. a. 2006, "Twice daily 0.2% brimonidine- 0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension", Arch Ophthalmol, vol. 124, pp. 1230-1238.

Pressure Lowering Medications


Mirza GE, K. S. T. E. 2000, "Comparison of the effects of 0.5% timolol malaete, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects", *J Glaucoma*, vol. 9, pp. 45-50.


Netland PA, R. S. S. E. e. a. 2003, "Travoprost Study Group: Response to travoprost in black and non black patients with open angle glaucoma or ocular hypertension", *Adv Ther*, vol. 20, pp. 149-163.


Osborne NN and Chidlow G 1996, "Do beta-adrenoceptors and serotonin 5-HT_{1A} receptors have similar functions in the control of intraocular pressure in the rabbit?", *Ophthalmologica*, vol. 210, pp. 308-314.

Osborne NN, W. J. C. G. e. a. 2004, "Effectiveness of levobetaxolol and timolol at blunting retinal ischemia is related to their calcium and sodium blocking activities: relevance to glaucoma", *Brain Res Bull*, vol. 62, pp. 525-528.


Schuman JS, K. G. L. R. e. a. 2005, "Efficacy and safety of a fixed combination of Travaprost 0.004%/Timolol 0.5% ophthalmic solution once daily for open angle glaucoma or ocular hypertension", Am J Ophthalmol, vol. 140, pp. 242-250.


South East Asia Glaucoma Interest Group 2008, Asia Pacific Glaucoma Guidelines, Second edn, Scientific Communications, Hong Kong.


Uusitalo H, K. M. R. A. e. a. 2006, "Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma", *Graefe's Arch Clin Exp Ophthalmol*, vol. 244, pp. 1491-1496.


Wandel TA, F. D. N. G. e. a. 1988, "Ocular hypotension efficacy of 0.25% levobunolol once-daily", *Ophthalmology*, vol. 95, pp. 252-254.


This book summarizes current literature about research and clinical science in glaucoma and it is a synopsis and translation of the research conducted by individuals who are known in each of their respective areas. The book is divided into two broad sections: basic science and clinical science. The basic science section examines bench- and animal-modeling research in an attempt to understand the pathogenesis of glaucoma. The clinical science section addresses various diagnostic issues and the medical, laser and surgical techniques used in glaucoma management.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: